InformedCitizen.usBeta
In committeeTaxesHealth care

Cameron’s Law

H.R. 1414 · House bill · Introduced Feb. 18, 2025

The Cameron’s Law would increase the tax credit from 25% to 50% for eligible testing costs for developers of drugs treating certain rare diseases or conditions.

What stands out

Loading…

These are patterns in public records, not proof that money changed a vote. The same rules apply to every member. How we decide

At a glance

Who it affects

  • Developers of drugs for certain rare diseases or conditions

Where it stands

In committee

Lobbying and money

No lobbying reported yet

Lobbyists report every three months, about 20 days after each quarter ends. We have January 2025 through September 2026 reports. Newer reports will be added once filed and published.

What it would do

Written with AI from the official summary by Congress's research office.

How South Carolina voted

No recorded roll-call vote on this bill yet.

Groups that lobbied on it and gave to SC's members

PAC, lobbyist campaign and qualifying employee money this election, shown separately and never added together. Lobbying reports name the bills a group worked on, not which side it took.

No lobbying reported yet. Lobbyists report every three months, about 20 days after each quarter ends. We have January 2025 through September 2026 reports. Newer reports will be added once filed and published.

Official record

Official title, sponsor and status
Official title
To amend the Internal Revenue Code of 1986 to restore the amount of the orphan drug tax credit.
Sponsor
Rep. Gottheimer, Josh (D-NJ)
Introduced
Feb. 18, 2025
Cosponsors
19
Committees
House Ways and Means Committee
Latest action
Feb. 18, 2025 · Referred to the House Committee on Ways and Means.
Congress.gov ↗
Official summary from the Congressional Research Service

Cameron's Law This bill increases the orphan drug tax credit to 50% (from 25%) of qualified clinical testing expenses paid or incurred in the development of drugs to treat certain rare diseases or conditions. As background, the Tax Cuts and Jobs Act reduced the orphan drug tax credit (for tax years after 2017) to 25% of qualified clinical testing expenses (e.g., wages, supplies, and certain contract expenses) paid or incurred in the development of drugs to treat certain rare diseases or conditions. For 2017 and prior tax years, the orphan tax credit was 50% of such expenses paid or incurred.

Summary on Congress.gov ↗
Everyone who lobbied on this bill (0 groups)

No lobbying report we have loaded names this bill. That doesn't mean no lobbying took place.

Lobbyists report every three months, about 20 days after each quarter ends. We have January 2025 through September 2026 reports. Newer reports will be added once filed and published. Reports for October through December 2026 are due January 20, 2027.